Bonus Biogroup (BBIXF) Ratios
Bonus Biogroup Ratios
BBIXF's free cash flow for Q2 2026 was $-4.13M. For the 2026 fiscal year, BBIXF's free cash flow was decreased by $-15.00K and operating cash flow was $-4.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.13 | 0.91 | 4.47 | 7.14 | 9.24 |
| Quick Ratio | 0.13 | 0.91 | 4.47 | 7.14 | 9.24 |
| Cash Ratio | 0.02 | 0.87 | 2.19 | 7.03 | 9.06 |
| Solvency Ratio | -1.03 | -1.59 | -1.72 | -1.98 | -4.45 |
| Operating Cash Flow Ratio | -1.07 | -2.70 | -4.47 | -3.78 | -4.54 |
| Short-Term Operating Cash Flow Coverage | -8.36 | -12.88 | -17.79 | -21.28 | -32.42 |
| Net Current Asset Value | $ -19.35M | $ -9.26M | $ 10.86M | $ 36.21M | $ 61.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.58 | 0.44 | 0.25 | 0.16 | 0.12 |
| Debt-to-Equity Ratio | -1.57 | 1.46 | 0.38 | 0.21 | 0.15 |
| Debt-to-Capital Ratio | 2.75 | 0.59 | 0.28 | 0.17 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.73 | 3.36 | 1.53 | 1.32 | 1.24 |
| Debt Service Coverage Ratio | -7.98 | -10.67 | -11.91 | -15.65 | -48.95 |
| Interest Coverage Ratio | -32.20 | -34.93 | -32.25 | -41.58 | -113.77 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| Net Debt to EBITDA | -0.44 | -0.13 | 0.06 | 1.19 | 0.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 108.19% | 99.96% | 100.65% | 104.47% | 139.15% |
| Return on Assets (ROA) | -158.60% | -118.88% | -63.55% | -51.87% | -86.34% |
| Return on Equity (ROE) | 432.38% | -399.97% | -97.35% | -68.64% | -106.69% |
| Return on Capital Employed (ROCE) | -1564.34% | -179.70% | -72.72% | -55.30% | -67.75% |
| Return on Invested Capital (ROIC) | -699.94% | -148.00% | -67.57% | -53.16% | -66.05% |
| Return on Tangible Assets | -158.60% | -118.92% | -63.59% | -51.90% | -86.34% |
| Earnings Yield | -14.57% | -22.06% | -14.54% | -29.96% | -12.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.50 | 2.76 | 1.97 | 1.72 | 1.03 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -243.29 | -132.25 | -185.74 | -211.67 | -355.82 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 243.29 | 132.25 | 185.74 | 211.67 | 355.82 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.05 | -0.07 |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.06 | -0.08 |
| Dividend Paid and CapEx Coverage Ratio | -1244.42 | -62.50 | -32.04 | -4.51 | -6.86 |
| Capital Expenditure Coverage Ratio | -1244.42 | -62.50 | -32.04 | -4.51 | -6.86 |
| Operating Cash Flow Coverage Ratio | -1.68 | -2.10 | -2.37 | -2.41 | -3.23 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -8.89% | -17.22% | -13.87% | -27.25% | -6.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.86 | -4.53 | -6.88 | -3.34 | -8.10 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -29.68 | 18.13 | 6.70 | 2.29 | 8.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.25 | -5.81 | -7.21 | -3.67 | -15.99 |
| Price-to-Operating Cash Flow Ratio | -11.26 | -5.90 | -7.43 | -4.48 | -18.32 |
| Price-to-Earnings Growth (PEG) Ratio | -0.13 | 1.84 | 0.11 | 0.05 | -0.01 |
| Enterprise Value Multiple | -8.89 | -4.94 | -6.91 | -2.49 | -7.53 |
| Enterprise Value | 176.77M | 129.47M | 194.43M | 87.51M | 662.59M |
| EV to EBITDA | -8.89 | -4.94 | -6.91 | -2.49 | -7.53 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -11.83 | -5.96 | -7.14 | -2.49 | -14.52 |
| EV to Operating Cash Flow | -11.84 | -6.06 | -7.37 | -3.04 | -16.63 |
| Tangible Book Value Per Share | -0.01 | 0.01 | 0.03 | 0.09 | 0.15 |
| Shareholders’ Equity Per Share | -0.01 | 0.01 | 0.03 | 0.09 | 0.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.04 | -0.02 | -0.02 | -0.06 | -0.16 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.08 | 1.00 | 0.96 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.61 | 0.77 | 0.93 | 0.74 | 0.44 |
Currency in ILS
